| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | ATRA | FIMM | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.0024 | 1 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | -0.0022 | 1 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.0021 | 1 |